Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/9667264/ below:

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

Clinical Trial

Affiliations

• ¹ Wayne State University Medical Center, Detroit, MI, USA.

• PMID: 9667264
• DOI: 10.1200/JCO.1998.16.7.2459

Item in Clipboard

Clinical Trial

A J Wozniak et al. J Clin Oncol. 1998 Jul.

• ¹ Wayne State University Medical Center, Detroit, MI, USA.

• PMID: 9667264
• DOI: 10.1200/JCO.1998.16.7.2459

Item in Clipboard

Purpose: Cisplatin has played a major role in the treatment of non-small-cell lung cancer (NSCLC). This randomized trial was performed by the Southwest Oncology Group (SWOG) to determine whether the combination of vinorelbine and cisplatin has any advantage with regard to response rate, survival, and time to treatment failure over single-agent cisplatin in the treatment of patients with advanced NSCLC.

Methods: Between October 1993 and April 1995, 432 patients with advanced stage NSCLC were randomized to receive arm I (cisplatin 100 mg/m2 every 4 weeks) or arm II (cisplatin 100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2 weekly). All patients were chemotherapy-naive, had performance status (PS) 0 or 1, and had adequate hematologic, renal, and hepatic function.

Results: Four hundred fifteen patients were eligible and assessable. On arm I (cisplatin), there was a 12% partial response rate. Arm II (cisplatin and vinorelbine) had a 26% response rate (2% complete responses and 24% partial responses, P = .0002). There was a statistically significant advantage with regard to progression-free survival (median, 2 v 4 months; P = .0001) and overall survival (median, 6 v 8 months; P = .0018) for the cisplatin and vinorelbine arm. One-year survival was 20% for cisplatin alone and 36% for the combination arm. There was more hematologic toxicity on arm II of the study (81% grades 3 and 4 granulocytopenia v 5% on arm I). Other toxicities, such as renal insufficiency, ototoxicity, and nausea and vomiting, and neuropathy were similar.

Conclusion: The results of this study indicate that the combination of cisplatin and vinorelbine is a superior treatment when compared with single-agent cisplatin in the treatment of advanced NSCLC. Cisplatin and vinorelbine is the new standard for SWOG against which new therapies will be evaluated.

PubMed Disclaimer

• Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.

  Clark JI, Kancharla K, Qamar R, Fisher S, Hantel A, Panganiban J, Millbrandt L, Albain KS. Clark JI, et al. Lung Cancer. 2001 Nov;34(2):271-7. doi: 10.1016/s0169-5002(01)00251-3. Lung Cancer. 2001. PMID: 11679186 Clinical Trial.

• A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.

  Le Chevalier T, Pujol JL, Douillard JY, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Besson F, et al. Le Chevalier T, et al. Semin Oncol. 1994 Oct;21(5 Suppl 10):28-33; discussion 33-4. Semin Oncol. 1994. PMID: 7973766 Clinical Trial.

• Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.

  Lena MD, Ramlau R, Hansen O, Lorusso V, Wagner L, Barni S, Cristovao MM, Huber R, Alberola V, Mitrovic M, Colin C, Gasmi J. Lena MD, et al. Lung Cancer. 2005 Apr;48(1):129-35. doi: 10.1016/j.lungcan.2004.10.006. Epub 2004 Dec 21. Lung Cancer. 2005. PMID: 15777980 Clinical Trial.

• Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.

  Belani CP; TAX 326 Study Group. Belani CP, et al. Semin Oncol. 2002 Jun;29(3 Suppl 12):4-9. doi: 10.1053/sonc.2002.34255. Semin Oncol. 2002. PMID: 12170445 Review.

• Vinorelbine (Navelbine) in the treatment of non-small-cell lung cancer: studies with single-agent therapy and in combination with cisplatin.

  Gralla R, Harper P, Johnson S, Delgado FM. Gralla R, et al. Ann Oncol. 1999;10 Suppl 5:S41-5. doi: 10.1093/annonc/10.suppl_5.s41. Ann Oncol. 1999. PMID: 10582138 Review.

• Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.

  Helbekkmo N, Sundstrøm SH, Aasebø U, Brunsvig PF, von Plessen C, Hjelde HH, Garpestad OK, Bailey A, Bremnes RM; Norwegian Lung Cancer Study Group. Helbekkmo N, et al. Br J Cancer. 2007 Aug 6;97(3):283-9. doi: 10.1038/sj.bjc.6603869. Epub 2007 Jun 26. Br J Cancer. 2007. PMID: 17595658 Free PMC article. Clinical Trial.

• Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.

  Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N. Clegg A, et al. Thorax. 2002 Jan;57(1):20-8. doi: 10.1136/thorax.57.1.20. Thorax. 2002. PMID: 11809985 Free PMC article. Review.

• Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.

  Sørensen JB, Frank H, Palshof T. Sørensen JB, et al. Br J Cancer. 2008 Jul 8;99(1):44-50. doi: 10.1038/sj.bjc.6604421. Epub 2008 Jun 10. Br J Cancer. 2008. PMID: 18542078 Free PMC article.

• A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer.

  Si X, Wang J, Cheng Y, Shi J, Cui L, Zhang H, Huang Y, Liu W, Chen L, Zhu J, Zhang S, Li W, Sun Y, Wang H, Zhang X, Wang M, Yang L, Zhang L. Si X, et al. Ther Adv Med Oncol. 2020 Nov 24;12:1758835920965849. doi: 10.1177/1758835920965849. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33281949 Free PMC article.

• Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer.

  Garon EB. Garon EB. Lung Cancer. 2012 Sep;77(3):475-81. doi: 10.1016/j.lungcan.2012.06.007. Epub 2012 Jul 12. Lung Cancer. 2012. PMID: 22795702 Free PMC article. Review.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3